Generics 7

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Roflumilast manufacturers

7 products found

Filters

7 products found

roflumilast

Tablets 0.5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #12186
The activity of the company is based on the development of highly competitive processes for the manufacture of active ingredients with high added value that meet the strictest quality specifications. They manufacture under strict compliance with the environmental and occupational safety regulations in force in Europe. They focus on the pharmaceutical, hospital, diagnostic, fine chemical, and food fields. Its products are marketed in more than 70 countries.

Manufacturer usually replies in 7 days

roflumilast

Tablets 0.5mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #12186
The activity of the company is based on the development of highly competitive processes for the manufacture of active ingredients with high added value that meet the strictest quality specifications. They manufacture under strict compliance with the environmental and occupational safety regulations in force in Europe. They focus on the pharmaceutical, hospital, diagnostic, fine chemical, and food fields. Its products are marketed in more than 70 countries.

Manufacturer usually replies in 7 days

roflumilast

Cream 0.30 %

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
Dossier availability date: 2025
Manufacturer #21467

Manufacturer usually replies in 9 days

roflumilast

Tablets 0.5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Canada
GMP approvals
EU GMP
Comments
Reference product : Daxas (Takeda)
Manufacturer #278

The company has become a prominent partner of the pharmacy community in North America, with the fastest rising market share among generic leaders. It can provide best-in-class supply reliability thanks to production capacity. In more than 50 countries, it's available locally or through corporate partnerships. R&D expenditures range from $40 million to $50 million per year. They are dedicated to maintaining a customer satisfaction rate of over 95% by continuously enhancing supply chain efficiency.

Manufacturer usually replies in 7 days

roflumilast

Tablets for oral solution 500mcg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP
Unavailable markets
Albania
Registered in
Czech Republic
Manufacturer #281
It is a leading European pharmaceutical firm that strives to create a powerful global brand with innovative goods and services, as well as bold and pioneering activities, by working passionately to heal the lives they touch. The business was founded in the 1900s. In the interest of public health and the national economy, the firm launched the project to promote public awareness about the unintentional use of medications.

Manufacturer usually replies in 8 days

roflumilast

Tablets 500 mcg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19203

Manufacturer usually replies in 6 days

roflumilast

Tablets, film coated 0.5mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina
Available for
Distribution only
Manufacturer #16240
It is a laboratory that produces several product lines, such as allergy, cardiology, clinic, dermatology, gastroenterology, geriatrics, neurology, pediatrics, psychiatry, and urology, among others.

Manufacturer usually replies in 6 days

Roflumilast Manufacturers

Roflumilast belongs to a class of medication called phosphodiesterase inhibitors. Roflumilast is indicated as a treatment to control and prevent symptoms caused by lung disease such as chronic obstructive pulmonary disease which includes bronchitis. The symptoms include wheezing and shortness of breath. Roflumilast is advised as a prescription product as well as a generic prescription products. Before using this medication, the risk of taking the drug must be weighed against the benefits it provides. It is always recommended to consult a physician before taking Roflumilast as this medication may interact with other drugs and may aggravate the adverse reactions. Manufacturers market Roflumilast under the Brand name of Daliresp, Daxas, Libertek. Roflumilast is available in the dosage form of Tablet in dosage strength of 250 mcg and 500 mcg. Roflumilast tablet is taken by mouth, usually taken with or without food once a day. Each tablet is film coated and is supplied as white or off - white, round tablets engraved with first letter of brand name on one side and dosage strength on the other side. The recommended dose of Roflumilast in adults is one 500 mcg tablet per day. Roflumilast is not recommended for pediatric patients as safety and efficacy have not been established and moreover chronic obstructive pulmonary disease does not generally occur in children. This medication must be used regularly to show its response as it does not work immediately. After a 500-mcg dose, the bioavailability of Roflumilast is about 80% and attains maximum plasma concentration in 0.5 - 2 hours in fasting stage, and in fed state it is reduced by 40 % and time taken to reach maximum plasma concentration is increased by 1 hour. The roflumilast tablet is recommended to store at 20° C to 25° C (68° F - 77° F), with excursion permitted to 15° C to 30° C (59° F - 86° F),

Wholesale Price of Roflumilast

In U.S, the cost for Roflumilast oral tablet 250 mcg is around $ 276 for a supply of 20 tablets, with per unit cost available at $ 13.80 and the cost for a set of 28 tablets is $ 382.56 with per unit cost comes at $ 13.66 The whole sale price of Roflumilast oral tablet 500 mcg is around $ 409.20 for a quantity of 30 tablets with per unit cost available for $ 13.64 and the price for a set of 90 tablets is $ 1208.60 with per unit cost available for as low as $ 13.43 Roflumilast is categorized under patient assistance programs where the medication is sponsored by pharmaceutical companies where the drug is provided for free or at discounted rates to low income or underinsured people who fulfill the eligibility requirement.

Roflumilast - Mechanism of Action

Roflumilast is a phosphodiesterase inhibitor, due to its selective inhibition it has the ability to exhibit potential anti-inflammatory and anti-modulatory effects in the pulmonary system. It is believed that the increased levels of intracellular cyclic AMP are responsible for the effectiveness of Roflumilast.

Finding Roflumilast Manufacturers and Suppliers

To find a trustworthy partner in our business is one of the biggest challenges and to defeat that and to make one’s work / life easy in finding the reliable manufacturer and supplier of Roflumilast, one can visit the Pipelinepharma website which helps buyer in finding the dependable manufacturers and suppliers of Roflumilast. Pipelinepharma, which is a business-to-business (B2B) licensing marketplace for pharmaceutical products, quickly connects proprietor with the consumers for the business development. The buyer can filter the product names in user familiar and unified search engine by its country, category, therapeutic area, forms, dossier and its status, regulatory filings, approvals, and more.